Observational study finds TRL and Lp(a) harmful effects beyond LDL cholesterol levels — Evidence Review
Published in European Heart Journal, by researchers from Chalmers University of Technology
Researched by
— the AI search engine for science
Table of Contents
Scientists have identified blood protein patterns linked to TRL and Lp(a)—two fat-carrying particles—which may explain residual heart disease risk even after lowering LDL cholesterol. Related research broadly supports the idea that TRL and Lp(a) contribute to cardiovascular disease through mechanisms beyond cholesterol buildup, as shown by the original study and numerous prior studies.
- Multiple studies demonstrate that both TRL and Lp(a) are independently associated with increased atherosclerotic cardiovascular disease (ASCVD) risk, even after optimizing LDL cholesterol levels, suggesting the importance of targeting these particles for further risk reduction 1 3 4 5 6 9.
- TRL and Lp(a) share pro-inflammatory and atherogenic properties, and accumulating evidence indicates they may have greater harmful effects per particle compared to LDL, reinforcing the new study’s findings about their biological impact on vessel walls 1 3 4 5 6.
- Genetic and clinical research also highlights significant residual risk in individuals with well-controlled LDL when TRL or Lp(a) levels are elevated, and ongoing trials are investigating therapies that specifically target these particles 3 5 7 9.
Study Overview and Key Findings
Understanding why cardiovascular risk persists in some individuals despite optimal LDL cholesterol reduction is a critical challenge in heart disease prevention. The recent study from Chalmers University of Technology addresses this by examining the biological effects of different fat-carrying particles, beyond their cholesterol content. By analyzing protein patterns in blood, the researchers aimed to uncover mechanisms—especially those involving inflammation—that might account for residual risk and offer new preventive targets.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Chalmers University of Technology |
| Journal Name | European Heart Journal |
| Authors | Jakub Morze, Elias Björnson, Michael Y Mi, Martin Adiels, Giorgio E M Melloni, Gonçalo R da Silva, Andrzej Rynkiewicz, Nicholas A Marston, Marta Guasch-Ferré, Michael Y Tsai, Jerome I Rotter, Robert E Gerszten, Qi Sun, Frank B Hu, Rikard Landberg, Göran Bergström, Chris J Packard, Jan Borén, Clemens Wittenbecher |
| Population | Blood protein patterns in individuals with heart disease risk |
| Methods | Observational Study |
| Outcome | Blood protein patterns linked to heart disease risk |
| Results | TRL and Lp(a) show harmful effects beyond LDL cholesterol levels |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus scientific paper database (over 200 million papers) using targeted queries to identify research on TRL, Lp(a), and LDL cholesterol and their roles in cardiovascular disease. The specific search queries were:
- TRL heart disease mechanisms
- Lp(a) effects cardiovascular health
- LDL cholesterol limitations heart disease
Below is a summary table of key topics and findings from the related studies:
| Topic | Key Findings |
|---|---|
| What are the mechanisms by which TRL and Lp(a) contribute to heart disease? | - Both TRL and Lp(a) are causally associated with increased risk of cardiovascular events, acting through pro-inflammatory and pro-atherogenic mechanisms, including immune cell attraction and vessel wall inflammation 1 4 5 6. - TRL and Lp(a) often confer risk independent of, and sometimes greater than, LDL cholesterol—especially in individuals whose LDL is already well controlled 3 5 6 9. |
| How does lowering LDL cholesterol affect residual cardiovascular risk? | - Lowering LDL-C with statins or other therapies reduces cardiovascular risk, but significant residual risk remains, especially in those with elevated TRL or Lp(a) 1 4 5 10 13 14. - Cumulative LDL exposure is associated with CHD, but LDL reduction alone does not fully address all at-risk individuals 11 13 14. |
| Are TRL and Lp(a) more harmful per particle than LDL, and what are the implications? | - Genetic and clinical studies indicate TRL and Lp(a) are more atherogenic per particle than LDL, driving more inflammation and carrying additional risk 3 4 5 6. - New therapies are being developed to specifically lower Lp(a) and TRL, with ongoing trials assessing their impact on clinical outcomes 7 9. |
| What roles do inflammation and immune pathways play in the impact of blood lipoproteins? | - TRL, Lp(a), and LDL all contribute to vascular inflammation, but TRL and Lp(a) share specific inflammatory protein patterns that may be key to their residual risk effects 1 2 4 5. - Toll-like receptor 4 (TLR4) and other immune pathways are implicated in the inflammatory responses linked to these particles, representing potential therapeutic targets 2. |
What are the mechanisms by which TRL and Lp(a) contribute to heart disease?
The new study’s identification of overlapping protein patterns linked to TRL and Lp(a) aligns with extensive evidence that these particles drive vascular inflammation and atherogenesis. Multiple reviews and consensus statements underscore their causal roles, distinct from LDL, through mechanisms such as immune cell attraction and changes in vessel wall structure 1 4 5 6. This complements the new findings, emphasizing the importance of non-LDL lipid particles in cardiovascular disease.
- Both TRL and Lp(a) contain proteins that promote inflammation and atherogenic changes, which can accelerate atherosclerosis independently of LDL cholesterol levels 1 4.
- Genetic data support the causal role of TRL and Lp(a) in heart disease, with their risk impact persisting even with optimal LDL reduction 5 6.
- The pro-inflammatory properties of Lp(a) are partly attributed to oxidized phospholipids, and TRL remnants promote foam cell formation and immune activation 4 5.
- Recognition of these mechanisms is influencing the development of new therapeutic strategies aimed directly at TRL and Lp(a) 1 5.
How does lowering LDL cholesterol affect residual cardiovascular risk?
Lowering LDL cholesterol remains the mainstay of ASCVD prevention, but many patients experience cardiovascular events despite reaching guideline-recommended LDL levels 10 11 13 14. The literature and the new study agree that addressing TRL and Lp(a) is important for further risk reduction, as these particles contribute to residual risk through mechanisms beyond cholesterol burden.
- Statin-based and other LDL-lowering interventions significantly reduce nonfatal cardiovascular events and mortality but do not eliminate risk 13 14.
- Cumulative LDL exposure from youth through middle age is a strong predictor of CHD, but high TRL and Lp(a) can maintain risk even with low LDL 11.
- Residual risk is often attributable to elevated TRL and Lp(a), supporting the need for multi-faceted lipid management 1 5 6.
- Current guidelines and consensus statements suggest considering TRL and Lp(a) as additional risk factors in patients with controlled LDL but ongoing cardiovascular risk 5 8 9.
Are TRL and Lp(a) more harmful per particle than LDL, and what are the implications?
Recent genetic and clinical evidence indicates that TRL and Lp(a) may be more atherogenic per particle than LDL, which is consistent with the new study’s conclusions about their disproportionate contribution to residual risk 3 4 5 6. This has major implications for future risk assessment and treatment approaches.
- Mendelian randomization and polygenic score analyses show higher odds of CHD per standard deviation increase in TRL/Lp(a) compared to LDL 3.
- Patients with elevated TRL or Lp(a) have higher rates of vascular events, even when LDL is at target 3 4 5.
- New nucleic acid-based therapies (e.g., antisense oligonucleotides targeting Lp(a)) are in advanced clinical trials, aiming to test whether lowering these particles reduces events 7 9.
- Existing therapies (statins, PCSK9 inhibitors) have limited or variable effects on Lp(a), highlighting a gap in current management 9.
What roles do inflammation and immune pathways play in the impact of blood lipoproteins?
Both the new study and prior research indicate that inflammation is a key mediator of the harmful effects of TRL and Lp(a) 1 2 4 5. The shared protein patterns linked to immune cell attraction and vascular inflammation suggest common pathways that could be targeted for therapy.
- TRL and Lp(a) are associated with upregulation of inflammatory proteins and pathways, beyond what is seen with LDL 1 4 5.
- Toll-like receptor 4 (TLR4) has been identified as a critical regulator of myocardial inflammation, and may mediate part of the inflammatory response to these particles 2.
- Inflammatory changes induced by TRL and Lp(a) could explain their outsized impact on vessel wall pathology relative to their abundance 1 2 4.
- Understanding these pathways may inform new approaches to risk prediction and intervention in individuals with residual risk 1 2 5.
Future Research Questions
While the current research clarifies the importance of TRL and Lp(a) in residual cardiovascular risk and highlights shared inflammatory pathways, several important questions remain. Future studies are needed to determine whether targeting these pathways can improve outcomes, how best to measure and monitor risk, and which patient populations stand to benefit most from new interventions.
| Research Question | Relevance |
|---|---|
| Can targeting the shared inflammatory pathways of TRL and Lp(a) reduce residual cardiovascular risk? | Understanding whether interventions aimed at inflammation—specifically those pathways activated by TRL and Lp(a)—can lower event rates would clarify causality and guide new treatment strategies 1 2 4 5. |
| What are the clinical outcomes of novel Lp(a)-lowering therapies in patients with controlled LDL-C? | Early trials of Lp(a)-lowering agents are ongoing, but robust outcome data are needed to confirm if lowering Lp(a) translates to fewer cardiovascular events, particularly in those already at LDL targets 7 9. |
| How should TRL and Lp(a) be measured and monitored in routine clinical practice? | There is currently a lack of standardized assays and guidelines for TRL and Lp(a) measurement, which hinders risk stratification and implementation of personalized therapies 6 8. |
| Which populations benefit most from additional TRL or Lp(a) lowering beyond LDL reduction? | Identifying subgroups—such as those with diabetes, chronic kidney disease, or familial hyperlipidemia—who derive the greatest benefit would optimize therapy and resource allocation 4 5 8. |
| What is the long-term impact of TRL and Lp(a) lowering on atherosclerosis progression and event rates? | Longitudinal studies are needed to assess whether sustained lowering of these particles leads to measurable changes in plaque burden and lower incidence of heart attacks and strokes over time 3 7 9. |